ADHD Treatment Market Grow at a CAGR of 6.1% During 2018 to 2026

26/ago/2019 13:37:56 Optima Insights Contatta l'autore

The Attention Deficit Hyperactivity Disorder (ADHD) Treatment was valued at around US $ 15 billion at the end of 2018. With a CAGR of 6.1%.

ADHD, DSM-5 classified by the American Psychiatric Association (APA), characterized by patterns of hyperactivity, inattentions, and impulsivity. The worldwide prevalence of ADHD in children was around 2.3% and 2.8% among adults, in 2018. . With around the forecast period 2019-2026, with product development, product launches and more investment in research and development

6.1% in the forecast period Continuous rise in the adult ADHD population with many yet to be diagnosed and policies drafted at the national level are set to drive the market at CAGR of 6.1% throughout the forecast period. For example, the US government conducts national-level surveys assessments In 2016, the US government allocated funds of more than US $ 50 million to address the treatment requirements of individuals with psychological disorders. The National Health Services (NHS), UK allocated US $ 1.2 billion to set-up a five-year plan for aiding patients from mental illnesses.

During recent times, there is a growing awareness of mental illness. Parents are ready to go the extra mile to provide their children without any psychological problems. The market growth is set to boost during the forecast period from 2019 to 2026.

However, lack of accurate biomarkers for diagnosing ADHD and unknown genetic causes are still gray areas which have to be addressed. Due to this, the cost of diagnosis is also on the higher side. Besides, the cost of treatment is also likely to hamper the market growth. With more investment contribution towards R&D for developing and accurate diagnostic methods should drive the market during the coming years.

The ADHD Outlook Treatment Market 2019-2026, from Optima Insights, will offer comprehensive market growth to the forecast year 2026 based on market segmentation (Drug Class, Age, Distribution Channel, and Region). The report includes comprehensive profiling of companies involved in drug development, products of ADHD and pipeline information (inclusive of clinical trial data).

The drug class is used for ADHD can be classified as Stimulants and Non-stimulants. Stimulants include Lisdexamfetamine dimesylate, Dexmethylphenidate, Dextroamphetamine, Methylphenidate, and Amphetamine. While the non-stimulant types are Clonidine, Bupropion, Atomoxetine, and Guanfacine.

Stimulant drugs dominated the market share in the year 2018. The stimulant drugs always have upper hand over the non-stimulating drugs attributing to more efficacy. For example, Shire's Lisdexamfetamine ruled the ADHD drug sales comparable to the other drug lines. Owing to its efficacy, the prescription of stimulant drugs for treating ADHD is increasing. In the year 2018, the use of stimulant drugs was more than 4 million. Recently, the FDA approved Adhansia XR, a high dose (60mg) drug of Purdue Pharma for treating ADHD in children of around 6 years. With more clinical trials underway and govt.

However, the lack of evidence on long-term usage of stimulant drugs for ADHD treatment is still debatable. However, non-stimulants are growing in popularity among the US and European populace two to its long-lasting effect and considerably low-risk element. The non-stimulant drug therapies.

The ADHD is accompanied by frequent clinical visits and the physician consults. This is the fact, that hospital inpatient is less owing to lengthy treatment regimens. Thus, making patients rely on the pharmacies.

Especially in the US, the amount of prescriptions is increasing every year. Also, the number of ADHD patients in the US. The North American region is a country where it is possible to learn how to develop the ADHD patient. Following North America, European Market is also said to contribute to the market share. Both North America and US medical coverage policies contribute to the market, such as APAC and LAMEA, which are considered emerging markets with awareness yet to be created.

There are 16 Key Major Players including Pfizer, Prude Pharma LP, Novartis, Janssen Pharma, Takeda, Sunovion, Tris Pharma, etc. Also, there are 14 companies that are classified as New Market Entrants and Emerging Companies.

Download Sample Report @  https://www.optimainsights.org/sample-request/142-attention-deficit-hyperactivity-disorder-treatment-market

Key Developments:

In May 2019, FDA approved the Monarch eTNS System for ADHD treatment in children aged 7-12 yrs which will be commercialized by NeuroSigma, Inc.,

In June 2019, Researchers from Tehran University confirmed that saffron capsules offer the same effect as methylphenidate on ADHD.

In June 2019, Ironshore Pharmaceutical's DELEXIS® (novel drug delivery system) based JORNAY PM TM (methylphenidate HCl) extended-release capsules was launched in the US.

In June 2019, Haifa-based InnoSphere's patented medical "cap" provides promising results for ADHD treatment. The device is said to hit the market by 2022.

The Report Provides Key Insights on

  • History of the ADHD Treatment Market, 2015 to 2017
  • ADHD Treatment Market Growth till the year 2026
  • The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the ADHD Treatment Market
  • Analysis of potential growth segments which will drive the market
  • Landscape analysis of major companies, and new market entrants and companies which have disruptive technologies which can change the trend of the entire market
  • Key market approaches adopted by organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Any Questions Ask @  https://www.optimainsights.org/any-question/142-attention-deficit-hyperactivity-disorder-treatment-market

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Drug Type (Market Size and Forecast, and YoY Growth, (US $ Mn)

  • Non-Stimulants
    • Clonidine (Kapvay)
    • Guanfacine (Intuniv)
    • Bupropion
    • Atomoxetine (Strattera)
  • stimulants
    • Lisdexamfetamine dimesylate (Vyvanse)
    • Dexmethylphenidate
    • Dextroamphetamine (Dexedrine, ProCentra, Zenzedi)
    • Methylphenidate (Concerta, Daytrana)
    • Amphetamine (Adzenys XR ODT, Evekeo)

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Age Group (Market Size and Forecast, and YoY Growth, (US $ Mn)

  • Adult
  • Pediatric and neonates

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Distribution Channel (Market Size and Forecast, and YoY Growth, (US $ Mn)

  • E-commerce
  • Retail Pharmacies
  • Hospital Pharmacies
  • Specialty Clinics

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Geographic Region (Market Size and Forecast, and YoY Growth, (US $ Mn)

  • North America
  • europe
  • APAC
  • LAMEA

Attention Deficit Hyperactivity Disorder (ADHD) Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

  • Eli Lilly and Company
  • Pfizer Inc
  • Novartis AG
  • Takeda Pharmaceutical Company Ltd
  • Tris Pharma
  • Taisho Pharma
  • NEOS Therapeutics Inc
  • Noven Pharmaceuticals
  • Prude Pharma LP

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues We continually support our customers through the entire journey.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: info@optimainsights.org

https://www.optimainsights.org

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl